103 related articles for article (PubMed ID: 34628209)
1. Adequacy of samples obtained via percutaneous core-needle rebiopsy for EGFR T790M molecular analysis in patients with non-small cell lung cancer following acquired resistance to first-line therapy: A systematic review and meta-analysis.
Poudel B; Desman J; Aihara G; Weidman DI; Tsang A; Kovrizhkin K; Pereira T; Arun S; Pradeep T; Matin S; Liddell RP
Cancer Treat Res Commun; 2021; 29():100470. PubMed ID: 34628209
[TBL] [Abstract][Full Text] [Related]
2. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
[TBL] [Abstract][Full Text] [Related]
3. Tissue Adequacy and Safety of Percutaneous Transthoracic Needle Biopsy for Molecular Analysis in Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis.
Nam BD; Yoon SH; Hong H; Hwang JH; Goo JM; Park S
Korean J Radiol; 2021 Dec; 22(12):2082-2093. PubMed ID: 34564960
[TBL] [Abstract][Full Text] [Related]
4. Should We Perform Repeated Re-biopsy for the Detection of T790M Mutation?
Kim S; Kim SH; Kim J; Kim MH; Lee MK; Eom JS
Cancer Res Treat; 2023 Oct; 55(4):1190-1197. PubMed ID: 37080607
[TBL] [Abstract][Full Text] [Related]
5. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
[TBL] [Abstract][Full Text] [Related]
6. Biopsy on progression in patients with
Chu Q; Agha A; Devost N; Walton RN; Ghosh S; Ho C
Curr Oncol; 2020 Feb; 27(1):27-33. PubMed ID: 32218657
[TBL] [Abstract][Full Text] [Related]
7. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
[TBL] [Abstract][Full Text] [Related]
8. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
[TBL] [Abstract][Full Text] [Related]
9. Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.
Kim H; Chae KJ; Yoon SH; Kim M; Keam B; Kim TM; Kim DW; Goo JM; Park CM
Eur Radiol; 2018 Feb; 28(2):861-868. PubMed ID: 28786010
[TBL] [Abstract][Full Text] [Related]
10. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
Kogure Y; Shigematsu F; Oki M; Saka H
In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
[TBL] [Abstract][Full Text] [Related]
11. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
Zhou J; Li Y; Zhang Y; Dai H; Guo S
Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
[TBL] [Abstract][Full Text] [Related]
12. Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience.
Tokaca N; Barth S; O'Brien M; Bhosle J; Fotiadis N; Wotherspoon A; Thompson L; Popat S
J Thorac Oncol; 2018 Jan; 13(1):63-72. PubMed ID: 28989040
[TBL] [Abstract][Full Text] [Related]
13. Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.
Dal Maso A; Lorenzi M; Roca E; Pilotto S; Macerelli M; Polo V; Cecere FL; Del Conte A; Nardo G; Buoro V; Scattolin D; Monteverdi S; Urso L; Zulato E; Frega S; Bonanno L; Indraccolo S; Calabrese F; Conte P; Pasello G
Clin Lung Cancer; 2020 Jan; 21(1):1-14.e3. PubMed ID: 31601525
[TBL] [Abstract][Full Text] [Related]
14. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.
Kawamura T; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Nakajima T; Ohde Y; Endo M; Takahashi T
Cancer Sci; 2016 Jul; 107(7):1001-5. PubMed ID: 27145431
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
16. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
[TBL] [Abstract][Full Text] [Related]
17. Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors.
Wagener-Ryczek S; Heydt C; Süptitz J; Michels S; Falk M; Alidousty C; Fassunke J; Ihle MA; Tiemann M; Heukamp L; Wolf J; Büttner R; Merkelbach-Bruse S
BMC Cancer; 2020 May; 20(1):408. PubMed ID: 32397977
[TBL] [Abstract][Full Text] [Related]
18. Detection of Low-level EGFR c.2369 C > T (p.Thr790Met) Resistance Mutation in Pre-treatment Non-small Cell Lung Carcinomas Harboring Activating EGFR Mutations and Correlation with Clinical Outcomes.
Ye L; Mesbah Ardakani N; Thomas C; Spilsbury K; Leslie C; Amanuel B; Millward M
Pathol Oncol Res; 2020 Oct; 26(4):2371-2379. PubMed ID: 32506395
[TBL] [Abstract][Full Text] [Related]
19. The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations.
Yoshimura A; Yamada T; Okura N; Takeda T; Furutani W; Kubota Y; Shiotsu S; Hiranuma O; Nishioka N; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
BMC Cancer; 2018 Dec; 18(1):1241. PubMed ID: 30537950
[TBL] [Abstract][Full Text] [Related]
20. Intrapatient Molecular and Histologic Heterogeneity After First-generation or Second-generation TKI Therapy of NSCLC Patients: Potential Clinical Impact on Subsequent third-generation TKI Treatment.
Iacono D; Osman GA; Migliorino MR; Grillo L; Remotti D; Nunnari J; Ricciardi S; Rossi A; Mancuso A; Graziano P; Di Lorenzo A; Bronzini M; Signora M; Leone A
Am J Clin Oncol; 2019 Nov; 42(11):845-850. PubMed ID: 31644442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
